Muruganathan A, Tiwaskar Mangesh
Adjunct Professor, Tamil Nadu Dr. MGR Medical University, Chennai, Tamil Nadu.
Consultant Physician and Diabetologist, Asian Heart Institute, Mumbai, Maharashtra.
J Assoc Physicians India. 2016 Sep;64(9):49-52.
While the incidence and prevalence of stroke is gradually decreasing in the western world, a parallel increase is seen in the developing world. It is a matter of special concern to us as approximately 20-30% of stroke occur in people younger than 45 years in India. Indians are prone to higher stroke risk because of urbanization, diabetes, cigarette smoking and high incidence of hypertension. Unfortunately, there is an inadequate awareness about the risk of stroke with hypertension among general public. Hypertension is considered to be the most important risk factor for stroke, and all forms of hypertension are associated with an increased risk of both ischemic and haemorrhagic stroke. The presence of hypertension also worsens mortality in stroke. Recently, it has been increasingly observed that controlling blood pressure variability (BPV) is equally important as achieving BP reduction, and an increased BPV has been shown to increase stroke risk. Thus, effective treatment option for stroke prevention should include drugs which can reduce BPV as well. The landmark ASCOT-BPLA trial reported that the calcium channel blocker amlodipine decreases stroke risk in hypertensive patients, and attributed this beneficial effect to its effective lowering of BPV. Such beneficial effects of amlodipine were replicated in other trials as well and thus it becomes an important drug from an Indian perspective. In this review, we analyse published literature and present a picture on the effect of amlodipine in the stroke prevention in hypertensive patients.
虽然在西方世界中风的发病率和患病率正在逐渐下降,但在发展中世界却出现了相应的上升。这是我们特别关注的问题,因为在印度约20%-30%的中风发生在45岁以下的人群中。由于城市化、糖尿病、吸烟以及高血压的高发病率,印度人更容易面临更高的中风风险。不幸的是,普通公众对高血压引发中风风险的认识不足。高血压被认为是中风最重要的风险因素,所有类型的高血压都与缺血性和出血性中风风险的增加有关。高血压的存在也会使中风的死亡率升高。最近,人们越来越多地观察到,控制血压变异性(BPV)与降低血压同样重要,并且已经表明血压变异性增加会增加中风风险。因此,预防中风的有效治疗选择应包括也能降低血压变异性的药物。具有里程碑意义的ASCOT-BPLA试验报告称,钙通道阻滞剂氨氯地平可降低高血压患者的中风风险,并将这种有益作用归因于其有效降低血压变异性。氨氯地平的这种有益作用在其他试验中也得到了验证,因此从印度的角度来看它成为一种重要的药物。在这篇综述中,我们分析已发表的文献,并呈现氨氯地平在预防高血压患者中风方面作用的情况。